
    
      The clinical phase of the study comprises up to 2 weeks of screening for patient's
      eligibility, a 2-week run-in period , a 8-week double-blind treatment period, and a 4-week
      safety follow-up.

      Patients report their IBS-related symptoms daily from run-in until end of treatment.
    
  